2019
Association of Immunosuppression and Human Immunodeficiency Virus (HIV) Viremia With Anal Cancer Risk in Persons Living With HIV in the United States and Canada
Hernández-Ramírez RU, Qin L, Lin H, Leyden W, Neugebauer RS, Althoff KN, Hessol NA, Achenbach CJ, Brooks JT, Gill MJ, Grover S, Horberg MA, Li J, Mathews WC, Mayor AM, Patel P, Rabkin CS, Rachlis A, Justice AC, Moore RD, Engels EA, Silverberg MJ, Dubrow R, Benson C, Bosch R, Kirk G, Mayer K, Grasso C, Hogg R, Harrigan P, Montaner J, Yip B, Zhu J, Salters K, Gabler K, Buchacz K, Li J, Gebo K, Moore R, Moore R, Rodriguez B, Horberg M, Silverberg M, Thorne J, Rabkin C, Margolick J, Jacobson L, D’Souza G, Klein M, Kroch A, Burchell A, Betts A, Lindsay J, Hunter-Mellado R, Mayor A, Gill M, Deeks S, Martin J, Li J, Brooks J, Saag M, Mugavero M, Willig J, Mathews W, Eron J, Napravnik S, Kitahata M, Crane H, Drozd D, Sterling T, Haas D, Rebeiro P, Turner M, Justice A, Dubrow R, Fiellin D, Gange S, Anastos K, Moore R, Saag M, Gange S, Kitahata M, Althoff K, Horberg M, Klein M, McKaig R, Freeman A, Moore R, Freeman A, Kitahata M, Van Rompaey S, Crane H, Drozd D, Morton L, McReynolds J, Lober W, Gange S, Althoff K, Lee J, You B, Hogan B, Zhang J, Jing J, Humes E, Coburn S. Association of Immunosuppression and Human Immunodeficiency Virus (HIV) Viremia With Anal Cancer Risk in Persons Living With HIV in the United States and Canada. Clinical Infectious Diseases 2019, 70: 1176-1185. PMID: 31044245, PMCID: PMC7319056, DOI: 10.1093/cid/ciz329.Peer-Reviewed Original ResearchConceptsAnal cancer riskHIV RNA measuresCancer riskPeak CD4North American AIDS Cohort CollaborationRNA measuresHIV-1 RNA levelsHuman immunodeficiency virus (HIV) viremiaOncogenic human papillomavirus (HPV) infectionAnal cancer developmentAssociation of immunosuppressionTime-updated CD4T-cell countsHuman papillomavirus infectionHuman immunodeficiency virusCohort CollaborationPapillomavirus infectionImmunodeficiency virusImmunoregulatory controlCD4Cox modelCancer promotionUseful markerCancer developmentRNA levels
2015
Thirty-Day Postoperative Mortality Among Individuals With HIV Infection Receiving Antiretroviral Therapy and Procedure-Matched, Uninfected Comparators
King JT, Perkal MF, Rosenthal RA, Gordon AJ, Crystal S, Rodriguez-Barradas MC, Butt AA, Gibert CL, Rimland D, Simberkoff MS, Justice AC. Thirty-Day Postoperative Mortality Among Individuals With HIV Infection Receiving Antiretroviral Therapy and Procedure-Matched, Uninfected Comparators. JAMA Surgery 2015, 150: 343-351. PMID: 25714794, PMCID: PMC5015449, DOI: 10.1001/jamasurg.2014.2257.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virus (HIV) infectionCD4 cell countImmunodeficiency virus infectionAntiretroviral therapyPostoperative mortalityHIV infectionHIV-1 RNAIncidence rate ratiosUninfected patientsVirus infectionCell countUninfected comparatorsSurgical outcomesSurgical proceduresCD4 cell count strataCharlson Comorbidity Index scoreCommon inpatient surgical proceduresHIV-1 RNA levelsThirty-day postoperative mortalityUndetectable HIV-1 RNAVeterans Health Administration healthcare systemElectronic medical record dataCombination antiretroviral therapyComorbidity Index scoreCoronary artery bypass
2013
HIV Infection and the Risk of Acute Myocardial Infarction
Freiberg MS, Chang CC, Kuller LH, Skanderson M, Lowy E, Kraemer KL, Butt AA, Goetz M, Leaf D, Oursler KA, Rimland D, Barradas M, Brown S, Gibert C, McGinnis K, Crothers K, Sico J, Crane H, Warner A, Gottlieb S, Gottdiener J, Tracy RP, Budoff M, Watson C, Armah KA, Doebler D, Bryant K, Justice AC. HIV Infection and the Risk of Acute Myocardial Infarction. JAMA Internal Medicine 2013, 173: 614-622. PMID: 23459863, PMCID: PMC4766798, DOI: 10.1001/jamainternmed.2013.3728.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusAcute myocardial infarctionRisk of AMIFramingham risk factorsUninfected veteransRisk factorsMyocardial infarctionAMI eventsHIV statusVeterans Aging Cohort Study Virtual CohortHIV-1 RNA levelsStandard Framingham risk factorsIncident acute myocardial infarctionIncidence of AMISubstance useBaseline cardiovascular diseaseCD4 cell countHepatitis C infectionBody mass indexHIV-1 RNACopies/mLHIV-positive veteransTime-updated analysisDecade of ageRace/ethnicityPredictive Accuracy of the Veterans Aging Cohort Study Index for Mortality With HIV Infection
Justice AC, Modur SP, Tate JP, Althoff KN, Jacobson LP, Gebo KA, Kitahata MM, Horberg MA, Brooks JT, Buchacz K, Rourke SB, Rachlis A, Napravnik S, Eron J, Willig JH, Moore R, Kirk GD, Bosch R, Rodriguez B, Hogg RS, Thorne J, Goedert JJ, Klein M, Gill J, Deeks S, Sterling TR, Anastos K, Gange SJ. Predictive Accuracy of the Veterans Aging Cohort Study Index for Mortality With HIV Infection. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2013, 62: 149-163. PMID: 23187941, PMCID: PMC3619393, DOI: 10.1097/qai.0b013e31827df36c.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAlanine TransaminaseAnti-Retroviral AgentsAspartate AminotransferasesBiomarkersCD4 Lymphocyte CountCohort StudiesCreatinineFemaleHemoglobinsHepatitis CHIV InfectionsHIV-1HumansKaplan-Meier EstimateMaleMiddle AgedNorth AmericaPlatelet CountPredictive Value of TestsRisk AssessmentRNA, ViralSex FactorsConceptsNet reclassification improvementVeterans Aging Cohort Study (VACS) IndexVeterans Affairs Healthcare SystemAntiretroviral therapyPatient subgroupsNorth American AIDS Cohort CollaborationHIV-1 RNA levelsStudy indicesObserved mortalityPrior ART exposureVACS Index scoreHIV-1 RNAImportant patient subgroupsRisk of mortalityHealthcare systemDiverse patient subgroupsCohort CollaborationHIV biomarkersVACS IndexHIV infectionOrgan injuryParametric survival modelsART exposureReclassification improvementC-statistic
2011
FIB-4 Index Is Associated with Hepatocellular Carcinoma Risk in HIV-Infected Patients
Park LS, Tate JP, Justice AC, Lo Re V, Lim JK, Bräu N, Brown ST, Butt AA, Gibert C, Goetz MB, Rimland D, Rodriguez-Barradas MC, Dubrow R. FIB-4 Index Is Associated with Hepatocellular Carcinoma Risk in HIV-Infected Patients. Cancer Epidemiology Biomarkers & Prevention 2011, 20: 2512-2517. PMID: 22028407, PMCID: PMC3237927, DOI: 10.1158/1055-9965.epi-11-0582.Peer-Reviewed Original ResearchConceptsHigh FIB-4C virus infectionFIB-4Hepatocellular carcinomaVirus infectionRisk factorsHigh riskVeterans Affairs Central Cancer RegistryAlcohol abuse/dependencyHIV-1 RNA levelsHepatitis B virus infectionHepatitis C virus infectionVeterans Aging Cohort StudyDevelopment of HCCLow FIB-4Multivariate-adjusted HRNoninvasive laboratory testsAntiretroviral therapy useFIB-4 indexB virus infectionIndependent risk factorHCC risk factorsAging Cohort StudyIncident HCC casesCentral Cancer RegistryRisk of Heart Failure With Human Immunodeficiency Virus in the Absence of Prior Diagnosis of Coronary Heart Disease
Butt AA, Chang CC, Kuller L, Goetz MB, Leaf D, Rimland D, Gibert CL, Oursler KK, Rodriguez-Barradas MC, Lim J, Kazis LE, Gottlieb S, Justice AC, Freiberg MS. Risk of Heart Failure With Human Immunodeficiency Virus in the Absence of Prior Diagnosis of Coronary Heart Disease. JAMA Internal Medicine 2011, 171: 737-743. PMID: 21518940, PMCID: PMC3687533, DOI: 10.1001/archinternmed.2011.151.Peer-Reviewed Original ResearchConceptsIncident HF eventsHeart failureCoronary heart diseaseCopies/mLRisk factorsHIV infectionHF eventsHeart diseaseHigh riskVeterans Aging Cohort Study Virtual CohortHIV-1 RNA levelsRisk of HFCoronary heart disease eventsHuman immunodeficiency virus (HIV) infectionRNA levelsIncident heart failureOngoing viral replicationRetrospective cohort studyHeart disease eventsImmunodeficiency virus infectionHuman immunodeficiency virusVACS-VCVeteran EnrolleesCohort studyPrior diagnosis
2007
Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies
May M, Sterne JA, Sabin C, Costagliola D, Justice AC, Thiébaut R, Gill J, Phillips A, Reiss P, Hogg R, Ledergerber B, D'Arminio Monforte A, Schmeisser N, Staszewski S, Egger M. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS 2007, 21: 1185-1197. PMID: 17502729, PMCID: PMC3460385, DOI: 10.1097/qad.0b013e328133f285.Peer-Reviewed Original ResearchConceptsStart of HAARTCD4 cell countCell countHIV-1 RNA levelsHIV-1-infected patientsInitiation of HAARTTreatment-naive patientsDiagnosis of AIDSInjection drug useVirological responseHIV careNew AIDSCumulative incidenceParametric survival modelsClinical stageProspective studyRisk calculatorHAARTProgression rateTreatment changesPatientsDrug usePrognostic modelAIDSCells/
2004
Effect of Persistent Moderate Viremia on Disease Progression During HIV Therapy
Raffanti SP, Fusco JS, Sherrill BH, Hansen NI, Justice AC, D’Aquila R, Mangialardi WJ, Fusco GP. Effect of Persistent Moderate Viremia on Disease Progression During HIV Therapy. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2004, 37: 1147-1154. PMID: 15319674, DOI: 10.1097/01.qai.0000136738.24090.d0.Peer-Reviewed Original ResearchConceptsHIV-1 RNA levelsCopies/mLBaseline HIV-1 RNA levelsNew AIDSCopies/Moderate viremiaRNA levelsPlasma HIV-1 RNAAIDS-defining diagnosisAntiretroviral therapy historyActive antiretroviral therapyUnited States cohortHIV-1 RNACells/Proportional hazards modelCD4 count changesImmunologic deteriorationAntiretroviral therapyCD4 countPrior AIDSUndetectable viremiaViral suppressionImmunologic statusHIV infectionClinical benefit
2001
Clinical Importance of Provider-Reported HIV Symptoms Compared With Patient-Report
Justice AC, Chang CH, Rabeneck L, Zackin S. Clinical Importance of Provider-Reported HIV Symptoms Compared With Patient-Report. Medical Care 2001, 39: 397-408. PMID: 11329526, DOI: 10.1097/00005650-200104000-00010.Peer-Reviewed Original ResearchConceptsPatient-reported symptomsHIV-1 RNA levelsCD4 cell countRecent hospitalizationCell countSymptom ChecklistAdverse drug event monitoringRNA levelsCombination antiviral therapyHealth-related qualityPhysical health scalesHIV diseaseHIV infectionAntiviral therapyHRQOL subscalesMulticenter studyHIV symptomsClinical managementPatient reportsHospitalizationPatientsClinical importanceHealth ScaleSecondary analysisSymptoms